San Francisco, CA and Boston, MA, May 27, 2026 (Globe Newswire) -- Apogee Therapeutics has entered a strategic financing collaboration with Blackstone Life Sciences valued at $1.3 billion. The agreement will support Phase 3 development and potential commercialization of its immunology candidate zumilokibart. The funding is intended to accelerate late-stage clinical progress and prepare the program for possible market launch. Read full article here.

Springdale, AR, May 28, 2026 (PR Newswire) -- NOWDiagnostics has appointed Lisa Nibauer as its new chief executive officer. The leadership change is intended to guide the company’s next phase of innovation and organizational transformation. NOWDiagnostics aims to accelerate development and commercialization of its diagnostic technologies under the new leadership. Read full article here.

South San Francisco, CA, June 2, 2026 (NewLimit) -- NewLimit has secured $435 million in funding in a round led by Founders Fund to accelerate development of its longevity-focused platform. The capital will support advancement of programs aimed at reprogramming cells to address age-related diseases. The financing is expected to expand research capabilities and advance the company’s long-term therapeutic pipeline. Read full article here.

Exton, PA, June 1, 2026 (PR Newswire) -- West Pharmaceutical Services has appointed Michel Lagarde as its new president and chief executive officer. The leadership transition is intended to guide the company’s strategic direction and operational execution. West aims to continue expanding its global pharmaceutical packaging and delivery systems business under new leadership. Read full article here.

Boulder, CO, June 1, 2026 (PR Newswire) -- Edgewise Therapeutics has agreed to divest its Sevasemten asset in a transaction valued at up to $2.65 billion. The deal is designed to strengthen the company’s financial position and streamline its strategic focus on cardiovascular drug development. Following the sale, Edgewise plans to concentrate resources on advancing its heart-related therapeutic pipeline. Read full article here.

Cambridge, MA, May 14, 2026 (PR Newswire) -- Create Medicines has secured $122 million in Series B financing to accelerate development of its in vivo CAR-based therapeutic programs. The funding will support pipeline expansion across autoimmune disease and oncology indications. The investment is intended to advance the company’s platform toward clinical-stage development. Read full article here.

Franklin Lakes, NJ, May 18, 2026 (BD) -- BD has appointed Peter Menziuso as executive vice president and president of its BD Interventional segment. The leadership change is intended to support the company’s strategic priorities and strengthen its interventional business operations. The appointment aligns with BD’s efforts to drive growth and expand innovation across its medical technology portfolio. Read full article here.

South San Francisco, CA, May 18, 2026 (Globe Newswire) -- Quince Therapeutics has announced the acquisition of OrphAI alongside a private financing arrangement valued at up to $187 million. The transaction is designed to support advancement of the company’s pulmonary disease pipeline and broaden its development capabilities. The funding is expected to provide additional resources for clinical progress and future growth initiatives. Read full article here.

Malvern, PA, May 20, 2026 (MyChesCo) -- LifeScan has named Jonathan Salkin as its new chief executive officer as part of a leadership transition. The appointment is intended to support the company’s strategic direction and continued business development efforts. LifeScan aims to strengthen its position in diabetes management solutions under the new leadership structure. Read full article here.

Cambridge, MA, May 15, 2026 (Yahoo Finance) -- Biogen has completed its $5.3 billion acquisition of Apellis Pharmaceuticals. The deal strengthens Biogen’s presence in rare disease and complement-mediated disorder therapies. The company is expected to integrate Apellis’s portfolio into its broader neurology and specialty medicine strategy. Read full article here.

Brussels, Belgium, May 3, 2026 (UCB) -- UCB has announced plans to acquire Candid Therapeutics to strengthen its immunology pipeline. The transaction will add novel T-cell engager therapies aimed at addressing complex immune-mediated diseases. The deal is intended to broaden UCB’s research capabilities and support development of next-generation biologic treatments. Read full article here.

Humlebaek, Denmark, March 4, 2026 (Coloplast) -- Coloplast has appointed Gavin Wood as its new chief executive officer. The leadership transition is aimed at supporting the company’s long-term strategic and commercial objectives. Coloplast expects the appointment to help drive continued growth across its medical care and device businesses. Read full article here.

San Diego, CA, April 30, 2026 (Globe Newswire) -- ResMed (NYSE: RMD) signed a definitive agreement to acquire Noctrix Health for $340 million, adding the company's FDA de novo-classified Nidra device to its sleep health portfolio. Nidra is a noninvasive nerve stimulation device for moderate-to-severe restless legs syndrome, the world's third most prevalent sleep disorder, affecting approximately 17 million people in the U.S. ResMed said Noctrix's revenue growth rate and gro

Wayne, PA, April 30,2026 (Business Wire) -- Teleflex has appointed Jason Weidman as its new president and chief executive officer. The leadership transition is intended to guide the company’s strategic priorities and operational execution. The move supports Teleflex’s focus on advancing its medical device portfolio and driving long-term growth. Read full article here.

Mumbai, India and Jersey City, NJ, April 26, 2026 (Business Wire) -- Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon in a transaction valued at approximately $3.1 billion. The acquisition is aimed at strengthening Sun Pharma’s presence in women’s health and established medicines across global markets. The deal is expected to expand its specialty portfolio and improve its international commercial footprint. Read full article here.

Stamford, CT and Boston, MA, April 15, 2026 (Globe Newswire) -- Beeline Medicines officially launched with $300 million in Series A financing led by Bain Capital, debuting with a portfolio of five clinical and preclinical programs in-licensed from Bristol Myers Squibb. The company's lead asset, afimetoran, is a once-daily oral TLR7/8 inhibitor for systemic lupus erythematosus currently in Phase 2, with data expected in the second half of 2026 ahead of a planned pivotal prog

Montreal and Highland Park, NJ, April 21, 2026 (Yahoo Finance) -- Modulari-T Biosciences has named Tanya E. Borsuk as its new chief executive officer. The leadership appointment is aimed at advancing the company’s strategic direction and accelerating development of its therapeutic platforms. The move positions the company to expand its pipeline and operational capabilities in the next stage of growth. Read full article here.

New York, NY, April 19, 2026 (PRNewswire) -- Pulnovo Medical closed an oversubscribed $100 million strategic financing round led by Medtronic, alongside existing investors EQT, Qiming Venture Partners, OrbiMed, Gaorong Ventures, and Lilly Asia Ventures, and new investor HSG (formerly Sequoia China). Separately, Medtronic and Pulnovo entered into a commercial agreement contemplating potential future commercialization opportunities. Read full article here.

Boston, MA, and Singapore, April 22, 2026 (Paratus) -- Paratus Sciences has appointed Alicia Secor as president and chief executive officer. The company also expanded its leadership team to strengthen operational and strategic capabilities. These changes are intended to support Paratus’ next phase of growth and advancement of its scientific programs. Read full article here.

San Diego, CA, April 19, 2026 (Reuters) -- Eli Lilly has agreed to acquire Kelonia Therapeutics in a transaction valued at up to $7 billion. The deal includes an upfront payment along with additional milestone-based considerations tied to development progress. The acquisition is intended to strengthen Lilly’s oncology portfolio with next-generation cancer therapies. Read full article here.